Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PAM | P19021 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1960961 | 0.92 | DGKA (0.53) | CES1CES2DGKALMNAALDH1A1 | |
| SCHEMBL11558967 | 0.92 | DGKA (0.53) | CES1CES2DGKALMNAALDH1A1 | |
| SCHEMBL4653622 | 0.92 | DGKA (0.53) | CES1CES2DGKALMNAALDH1A1 | |
| SCHEMBL1962326 | 0.92 | DGKA (0.53) | CES1CES2DGKALMNAALDH1A1 | |
| SCHEMBL21571495 | 0.92 | DGKA (0.53) | CES1CES2DGKALMNAALDH1A1 | |
| SCHEMBL29101740 | 0.92 | DGKA (0.53) | CES1CES2DGKALMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL29219017 | 0.90 | DGKA (0.52) | CES1CES2DGKALMNAALDH1A1 | |
| SCHEMBL3340147 | 0.90 | DGKA (0.52) | CES1CES2DGKALMNAALDH1A1 | |
| Hydrazine SCHEMBL27464055 | 0.83 | CES1 (0.42) | CES1CES2DGKALMNAALDH1A1 | |
| SCHEMBL28005812 | 0.82 | FAAH (0.59) | LMNATP53CYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1719768-B1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| US-7973030-B2 | Benzothiazepine and benzothiepine compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1719768-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-0880575-A1 | MACHINING FLUID COMPOSITION AND METHOD OF MACHINING | CINCINNATI MILACRON INC. (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1998013444-A1 | MACHINING FLUID COMPOSITION AND METHOD OF MACHINING | CINCINNATI MILACRON INC. (US) | 1998-04-02 | — | — | WO | disclosed |
| US-5716917-A | AQUEOUS MIXTURE CONTAINING NATURAL ORGANIC LUBRICANT, SURFACTANTS AND WATER SOLUBLE CATIONIC MICROBIOCIDE | CINCINNATI MILACRON INC. (US) | 1998-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | SLC10A1, SREBF1, SPTLC1 | CES1 9/4885CES2 258/4885DGKA 2431/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | CES1 3/4885CES2 249/4885DGKA 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.